title: How accelerated atherosclerosis in SLE has changed our management of the disorder.
abstract: Basic science insights along with the assessment of risk factors so clearly documented by the Canadian and Hopkins cohorts in earlier papers of this special issue have clearly led to a change in the way rheumatologists manage SLE. This review will highlight specific ways it should alter our day to day treatment of lupus patients.
authors.affiliation: Division of Rheumatology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA, USA.
authors.forename: D S
authors.initials: DS
authors.lastname: Hallegua
authors.forename: D J
authors.initials: DJ
authors.lastname: Wallace
mesh_terms: D017152:Antibodies, Antiphospholipid / Q000378:metabolism; D001161:Arteriosclerosis / Q000209:etiology* / Q000276:immunology; D003327:Coronary Disease / Q000175:diagnosis / Q000209:etiology; D006710:Homocysteine / Q000097:blood; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000276:immunology / Q000628:therapy*; D012307:Risk Factors
chemical_list: D017152:Antibodies, Antiphospholipid; D000960:Hypolipidemic Agents; D007166:Immunosuppressive Agents; D006710:Homocysteine